The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3708-3717

  Watt, Torquil ^a   Cramon, Per ^a   Hegedüs, Laszlo ^b   Bjorner, Jakob Bue ^c,d,e   Bonnema, Steen Joop ^b   Rasmussen, Åse Krogh ^a   Feldt Rasmussen, Ulla ^a   Groenvold, Mogens ^d,f  

^a Rigshospitalet   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c QualityMetric   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e National Environmental Research Institute   (Denmark)

^f BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; CONTROLLED STUDY; EFFECT SIZE; EUTHYROIDISM; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SHORT FORM 36; SOCIAL ASPECT; THYROID DISEASE; THYROID SPECIFIC PATIENT REPORTED OUTCOME; THYROID SURGERY; TREATMENT RESPONSE; VALIDITY; AGED; GOITER; GRAVES OPHTHALMOPATHY; HEALTH SURVEY; MENTAL HEALTH; MIDDLE AGED; PSYCHOLOGY; PSYCHOMETRY; STANDARDS; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; FEMALE; GOITER; GRAVES OPHTHALMOPATHY; HEALTH SURVEYS; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; MENTAL HEALTH; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84907638318     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1322     Document Type: Article

References (53)

1. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889-1905.
2. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167.
3. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002;324:1417.
4. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887-900.
5. Barofsky I. Quality: its definition and measurement as applied to the medically ill. New York: Springer; 2012.
6. U. S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. Guidance for Industry. Patient-ReportedOutcome Measures: Use in Medical Product Development to Support Labeling Claims. Health Qual Life Outcomes. 2006;4:79.
7. Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52:187-192.
8. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
9. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217-S232.
10. Ware JE Jr, Kemp JP, Buchner DA, Singer AE, Nolop KB, Goss TF. The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults. Qual Life Res. 1998;7:235-244.
11. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102-109.
12. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves'orbitopathy. Clin Endocrinol (Oxf). 2005;63:395-402.
13. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011;364:1920-1931.
14. Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009;106:283-289.
15. Dayan CM, Panicker V. Novel insights into thyroid hormones from the study of common genetic variation. Nat Rev Endocrinol. 2009;5:211-218.
16. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623-1629.
17. Saravanan P, Visser TJ, Dayan CM. Psychological well-being correlates with free thyroxine but not free 3, 5, 3 '-triiodothyronine levels in patients on thyroid hormone replacement. J Clin Endocrinol Metab. 2006;91:3389-3393.
18. Abraham-Nordling M, Wallin G, Lundell G, Törring O. Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease. Eur J Endocrinol. 2007;156:173-179.
19. Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751-757.
20. Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest. 2004;27:259-264.
21. McMillan C, Bradley C, Razvi S, Weaver J. Evaluation of New Measures of the Impact of Hypothyroidism on Quality of Life and Symptoms: The ThyDQoL and ThySRQ. Value Health. 2008;11:285-294.
22. Watt T, Cramon P, Frendl DM, Ware JE Jr, ThyQoL group. Assessing health-related quality of life in patients with benign non-toxic goiter [published online May 23, 2014]. Best Pract Res Clin Endocrinol Metab. doi: http://dx.doi.org/10.1016/j.beem.2014.01.009.
23. Ljunggren JG, Törring O, Wallin G, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid. 1998;8:653-659.
24. Watt T, Groenvold M, Rasmussen AK, et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006;154:501-510.
25. Watt T, Hegedüs L, Rasmussen AK, et al. Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid. 2007;17:647-654.
26. Watt T, Rasmussen AK, Groenvold M, et al. Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing. Qual Life Res. 2008;17:1009-1017.
27. Watt T, Bjorner JB, Groenvold M, et al. Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination. Qual Life Res. 2009;18:483-496.
28. Watt T, Hegedüs L, Groenvold M, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol. 2010;162:161-167.
29. Watt T, Groenvold M, Hegedüs L, et al. Few items in the thyroidrelated quality of life instrument ThyPRO exhibited differential item functioning. Qual Life Res. 2014;23:327-338.
30. Tehrani M, Krummenauer F, Mann WJ, Pitz S, Dick HB, Kahaly GJ. Disease-specific assessment of quality of life after decompression surgery for Graves' ophthalmopathy. Eur J Ophthalmol. 2004;14:193-199.
31. Jaeschke R, Guyatt G, Cook D, Harper S, Gerstein HC. Spectrum of quality of life impairment in hypothyroidism. Qual Life Res. 1994;3:323-327.
32. Fahrenfort JJ, Wilterdink AM, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology. 2000;25:201-211.
33. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being inpatientson'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577-585.
34. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773-779.
35. Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001;54:391-398.
36. Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM. Test-retest reliability of the GO-QOL: a diseasespecific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol. 1999;52:875-884.
37. Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PM. On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res. 2003;12:349-362.
38. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;74:800-802.
39. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
40. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:S178-S189.
41. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
42. Kosinski M, Bjorner JB, Ware JE Jr, Batenhorst A, Cady RK. The responsiveness of headache impact scales scored using 'classical' and 'modern' psychometric methods: are-analysis of three clinical trials. Qual Life Res. 2003;12:903-912.
43. Deng N, Allison JJ, Fang HJ, Ash AS, Ware J E Jr. Usingthe bootstrap to establish statistical significance for relative validity comparisons among patient-reported outcome measures. Health Qual Life Outcomes. 2013;11:89.
44. Watt T, Cramon P, Bjorner JB, et al. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials. 2013;14:119.
45. Winther KH, Watt T, Bjørner JB, et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized clinical trial. Trials. 2014;15:115.
46. Winther KH, Bjorner JB, Bonnema SJ, et al. Development of acomposite thyroid-specific quality of life scale for a randomized controlled trial among hypothyroid patients with chronic autoimmune thyroiditis, based on the ThyPRO questionnaire. In: Proceedings from the International Society of Quality of Life Research; October 9-12, 2013, Abstract 104.4; Miami, FL.
47. SAS Institute Inc. SAS/STAT 9.3 User's Guide. Cary, NC: SAS Institute Inc; 2011.
48. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes. 2006;4:89.
49. Dattani R, Slobogean GP, O'Brien PJ, et al. Psychometric analysis of measuring functional outcomes in tibial plateau fractures using the Short Form 36 (SF-36), Short Musculoskeletal Function Assessment (SMFA) and the Western Ontario McMaster Osteoarthritis (WOMAC) questionnaires. Injury. 2013;44:825-829.
50. Lee CF, Luo N, Ng R, et al. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. Qual Life Res. 2013;22:1745-1751.
51. Madeley NJ, Wing KJ, Topliss C, Penner MJ, Glazebrook MA, Younger AS. Responsiveness and validity of the SF-36, Ankle Osteoarthritis Scale, AOFAS Ankle Hindfoot Score, and Foot Function Index in end stage ankle arthritis. Foot Ankle Int. 2012;33:57-63.
52. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920-980.
53. Hegedüs L. Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am. 2009;38:355-371, ix.